- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01118221
Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Rehabilitation of IPF Patients: Effects of Exercise and Oxidant Stress
The incidence and prevalence of IPF increase exponentially with age, and IPF occurs more often in older males. Cigarette smoking and environmental dust exposures are known risk factors for developing IPF. For example, the recently deployed military population, as it ages, is at especially increased risk of IPF. No effective therapies exist, although lung transplantation is used to extend survival of selected patients.
Defining specific therapy to improve exercise tolerance and dyspnea in IPF patients is thus an urgent priority of veteran-oriented research programs.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Chronic lung disease is common in the veteran population. While chronic obstructive pulmonary disease (COPD) is most prominent, fibrotic lung diseases, typified by idiopathic pulmonary fibrosis (IPF), are clearly increasing. We have developed extensive experience with a VA idiopathic pulmonary fibrosis (IPF) population in the context of a randomized, controlled clinical trial of vasodilator therapy.
Based on the current literature and our preliminary experience with exercise testing in IPF patients, we hypothesize that:
Formal pulmonary rehabilitation (i.e., an aerobic exercise program) will result in improved outcomes for IPF patients, demonstrable as an:
- Increase in exercise tolerance as quantified by 6-minute walk test (MWT) distance;
- Decrease in post-exercise dyspnea as quantified by the Borg dyspnea scale; and an
- Overall subjective improvement in quality of life as quantified by Saint George's Respiratory Questionnaire.
Metabolic and physiologic mechanisms of improved exercise tolerance and decreased dyspnea will include:
- More efficient oxygen metabolism demonstrated by maximum O2 uptake (VO2max);
- Decreased post-exercise oxidant stress demonstrated by post-exercise isoprostanes and plasma total antioxidant capacity (TAC); and,
- Maintenance of maximum inspiratory and expiratory pressures (PInmax and PExmax).
Our Specific Objectives are:
To investigate formal pulmonary rehabilitation and exercise tolerance in IPF patients
The following important endpoints will be assessed to test the working hypothesis that pulmonary rehabilitation improves exercise capacity and lessens dyspnea:
- 6-MWT distance;
- Dyspnea index; and,
- Quality of life (Saint George's Respiratory Questionnaire [SGRQ] and International Physical Activity Questionnaire [IPAQ]).
- To assess changes in oxygen uptake, markers of oxidant stress and pulmonary function resulting from pulmonary rehabilitation
To test the working hypothesis that improved outcomes are associated with more efficient O2 utilization, decreased markers of oxidant stress and maintained effort dependent pulmonary function, the following variables will be measured:
- Peak oxygen uptake (VO2peak) during constant load exercise;
- Markers of oxidant stress, including plasma and urine isoprostanes; and,
- Maximum inspiratory and expiratory pressures (PInmax and PExmax). Completion of these Specific Objectives will position our research group to conduct future studies of 1) mechanisms of exercise limitation and 2) antioxidant therapies, both in this defined population and those who are at risk of developing pulmonary fibrosis. The long term impact of this application is thus to develop effective pulmonary rehabilitation strategies for IPF patients, based on knowledge of underlying changes in oxygen metabolism and oxidant stress.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Miami, Florida, Forenede Stater, 33125
- VA Medical Center, Miami
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Clinical presentation consistent with IPF with onset between three months and 48 months prior to screening.
- Diagnosis made by high-resolution computed tomographic scan showing highly probable IPF.
- Absence of severe pulmonary hypertension (i.e., PAsys must be less than 55 mm Hg, based on echocardiography) and absence of decompensated right heart failure (NYHA class I or II acceptable).
- Age 40 through 80, inclusive.
- Abnormal pulmonary function tests (FVC 40-90% predicted or DLCO 30-90% predicted or impaired gas exchange with rest or exercise).
- Six-minute walk distance 150 m and 500 m.
- Worsening as demonstrated by any one of the following within the past year: > 10% decrease in percent predicted forced vital capacity or worsening dyspnea at rest or upon exertion, based on history.
- Ability to understand and sign a written informed consent form and comply with the requirements of the study.
- Absence of clinical features suggesting infection, neoplasm, sarcoidosis or collagen-vascular disease.
Exclusion Criteria:
- Echocardiographic evidence of severe pulmonary hypertension (PAsys>55 mm Hg, based on echocardiography or TR velocity 3.2 m/sec).
- Severe heart failure (NYHA class III or IV or LVEF < 45%).
- Six-minute walk distance < 150 m or > 500 m.
- FEV1/FVC ratio < 0.7 at screening (post-bronchodilator).
- Residual volume > 100% predicted.
- Any condition other than IPF likely to result in the death of the participant within the next two years.
- History of unstable or deteriorating cardiac or neurologic disease.
- Pregnancy or lactation. Patients who are: (a) pregnant or (b) breast feeding are excluded from the study.
- Current treatment with corticosteroids (either oral or inhaled), Cytoxan, azathioprine, colchicine, pirfenidone, anti-tumor necrosis factor therapy or endothelin receptor blockers. Prior treatment is permitted, but at least four weeks of treatment washout prior to inclusion in this study are required.
- Investigational therapy for any indication within 28 days prior to enrollment.
- Degenerative arthritis, cerebrovascular accident or other limitation to mobility preventing completion of the 6-minute walk test.
- Oxygen saturation on room air <80% at rest.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm 1
enroll in pulmonary rehabilitation program
|
structured exercise program
|
Ingen indgriben: Arm 2
no structured exercise
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
6 Minute Walk Distance
Tidsramme: The 6-MWD will be measured at 0 and 3 months.
|
Change in 6 Minute Walk Distance from Baseline to 3 Months
|
The 6-MWD will be measured at 0 and 3 months.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Systemic Markers of Oxidant Stress
Tidsramme: Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months.
|
Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.
|
Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months.
|
Maximum Oxygen Uptake
Tidsramme: Maximum O2 uptake will be measured at 0 and 3 months.
|
Change in 6 peak O2 uptake from Baseline to 3 Months
|
Maximum O2 uptake will be measured at 0 and 3 months.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Robert M Jackson, MD, VA Medical Center, Miami
Publikationer og nyttige links
Generelle publikationer
- Jackson RM, Gomez-Marin OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, Cahalin LP, Cardenas DD. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. 2014 Jun;192(3):367-76. doi: 10.1007/s00408-014-9566-9. Epub 2014 Apr 5.
- Gaunaurd IA, Gomez-Marin OW, Ramos CF, Sol CM, Cohen MI, Cahalin LP, Cardenas DD, Jackson RM. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. 2014 Dec;59(12):1872-9. doi: 10.4187/respcare.03180. Epub 2014 Sep 2.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- O7467-R
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med pulmonary rehabilitation
-
Uskudar State HospitalIkke rekrutterer endnuLungesygdom | Lungerehabilitering | Telesundhed
-
Rostrum Medical Innovations Inc.Medical InitiativesIkke rekrutterer endnuSlag | Lungebetændelse | KOL | Akut lungeskade/akut respiratorisk distress syndrom (ARDS) | Ventilatorer, mekaniskeFrankrig, Forenede Stater, Østrig, Tjekkiet
-
Edwards LifesciencesRekrutteringTetralogi af Fallot | Pulmonal ventilinsufficiens | Pulmonal regurgitation | RVOT-anomali | Kompleks medfødt hjertefejlForenede Stater, Israel
-
Shirley Ryan AbilityLabWashington University School of MedicineRekruttering
-
Emory UniversityNational Institute on Aging (NIA)RekrutteringProdromal Alzheimers sygdomForenede Stater
-
Spaulding Rehabilitation HospitalNortheastern UniversityAfsluttetGanggenoptræning i sunde fag | Ganggenoplæring i slagtilfældeoverlevereForenede Stater
-
Universidad Pública de NavarraMutua NavarraUkendtSkulderpåvirkning | Rotator Cuff sygdomSpanien
-
The Hong Kong Polytechnic UniversityAfsluttet
-
Scuola Superiore Sant'Anna di PisaAzienda Ospedaliero, Universitaria PisanaAfsluttetKronisk sygdom | Genoptræning af slagtilfælde | Cerebrovaskulær ulykke (CVA)Italien
-
University Hospital, LinkoepingLinkoeping University; Ryhov County HospitalUkendt